F-18 FDG PET and PET/CT evaluation of response to chemotherapy in bone and soft tissue sarcomas

Clinical Nuclear Medicine

Volumn 33, Issue 1, 2008, Pages 8-13

  Iagaru, Andrei ^a,d   Masamed, Rinat ^a   Chawla, Sant P ^b   Menendez, Lawrence R ^a   Fedenko, Alex ^c   Conti, Peter S ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Midway Hospital Medical Center   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bone; F 18 FDG; PET CT; Sarcoma; Soft tissue

Indexed keywords

CISPLATIN; ESORUBICIN; FLUORODEOXYGLUCOSE F 18; IFOSFAMIDE; METHOTREXATE;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; OSTEOSARCOMA; POSITRON EMISSION TOMOGRAPHY; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; TUMOR NECROSIS;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BONE NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IFOSFAMIDE; MALE; MIDDLE AGED; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SARCOMA; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 37549018481     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31815c4fd4     Document Type: Article

References (16)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
2. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using -[18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
3. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83-101.
4. Franzius C, Sciuk J, Brinkschmidt C, et al. Evaluation of chemotherapy response in primary bone tumors with F-18 FDG positron emission tomography compared with histologically assessed tumor necrosis. Clin Nucl Med. 2000;25:874-881.
5. Schuetze SM, Rubin BP, Vernon C, et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer. 2005;103:339-348.
6. Schulte M, Brecht-Krauss D, Werner M, et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med. 1999;40:1637-1643.
7. Brisse H, Ollivier L, Edeline V, et al. Imaging of malignant tumours of the long bones in children: monitoring response to neoadjuvant chemotherapy and preoperative assessment. Pediatr Radiol. 2004;34:595-605.
8. Conti PS, Menendez LR, Ramanna L, et al. Use of positron emission tomography in the evaluation of cryosurgical treatment of musculoskeletal tumors. Radiology. 1999;213:118.
9. Bacci G, Ferrari S, Bertoni F, et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol. 2000;18:4-11.
10. Eilber FC, Rosen G, Eckardt J, et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol. 2001;19:3203-3209.
11. Vernon CB, Eary JF, Rubin BP, et al. FDG PET imaging guided re-evaluation of histopathologic response in a patient with high-grade sarcoma. Skeletal Radiol. 2003;32:139-142.
12. Issels RD, Meier TH, Muller E, et al. Ifosfamide induced stress response in human lymphocytes. Mol Aspects Med. 1993;14:281-286.
13. Drug Index (Professional) - Ifosfamide. Available at: http://www.bccancer.bc.ca/HPI/DrugDatabase/DrugIndexPro/Ifosfamide.htm. Accessed July 23, 2005.
14. Jones DN, McCowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluoring-18-FDG PET. J Nucl Med. 1996;37:1438-1444.
15. van Ginkel RJ, Hoekstra HJ, Pruim J, et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advance soft-tissue sarcoma. J Nucl Med. 1996;37:984-990.
16. Lindner NJ, Scarborough MT, Spanier SS, et al. Local host response in osteosarcoma after chemotherapy referred to radiographs, CT, tumour necrosis and patient survival. J Cancer Res Clin Oncol. 1998;124:575-580.